Clinical anti-inflammatory efficacy of arofylline, a new selective phosphodiesterase-4 inhibitor, in dogs with atopic dermatitis.

Abstract

Forty atopic dogs were studied for 28 days after the oral administration of four randomised treatments: (A) arofylline (1 mg/kg) twice daily for four weeks; (B) prednisone (0.5 mg/kg) twice daily for the first week, once a day during the second week and every 48 hours for the remaining two weeks; (C) prednisone following the same protocol but at a dose of 0.25 mg/kg; or (D) arofylline (1 mg/kg) twice daily for four weeks plus prednisone (0.25 mg/kg) following the same protocol as in (B) and (C). The degree of pruritus and skin lesions and the side effects were evaluated and graded from 0 to 3 before and weekly during the treatments. In all cases there was a progressive clinical improvement in the clinical signs, with no statistical differences among the four treatments. However, many of the dogs treated with arofylline vomited and had adverse gastrointestinal signs.

• Authors: L Ferrer, J Alberola, M Queralt, P Brazís, R Rabanal, J Llenas, A Puigdemont
• Journal: The Veterinary record (Vet Rec) Vol. 145 Issue 7 Pg. 191-4 (Aug 14 1999) ISSN: 0042-4900 [Print] England
• PMID: 10501583 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Glucocorticoids
• Phosphodiesterase Inhibitors
• Tablets
• Prednisolone

Topics

• Administration, Oral
• Animals
• Dermatitis, Atopic (drug therapy, veterinary)
• Dog Diseases (drug therapy)
• Dogs
• Drug Administration Schedule
• Drug Therapy, Combination
• Female
• Glucocorticoids (administration & dosage, therapeutic use)
• Male
• Phosphodiesterase Inhibitors (administration & dosage, therapeutic use)
• Prednisolone (administration & dosage, therapeutic use)
• Tablets
• Treatment Outcome